# Ophiomics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ophiomics

- Industry: Biotechnology
- Headquarters: Lisbon, Portugal
- Website: www.ophiomics.com/
- Latest round: Series A (Jan 18, 2023)
- Investors on record: 1

## About

Based in Lisboa, Portugal, and co-founded by osé Pereira Leal and Joana Cardoso Vaz in 2015, Ophiomics operates as a Medtech company developing cancer diagnostic products and services. In January 2023, the firm raised its series A funding led by investor BlueCrow Capital. The firm as of October 2023, is led by its CEO, Jose Leal.

The clinical-stage Medtech company develops and offers diagnostic products and services that incorporate genomics, artificial intelligence, and bioinformatics to support cancer diagnostics, prognostics, treatment selection, and clinical monitoring. By leveraging the power of genomics and machine learning and by harnessing the potential of AI-driven in vitro diagnostic (IVD) tests, Ophiomics aims to discover biomarkers that address unmet clinical needs. These biomarkers are integrated with clinical variables, ensuring their solutions are accessible and can seamlessly integrate into routine clinical practice. Their product, HepatoPredict, is designed to support the decision of liver transplantation in Hepatocellular carcinoma patients. The other products in the pipeline of Ophiomics include ESODetect for diagnosis and prognosis of Barrett's Esophagus, and HepatoDetect for liquid biopsy for early liver cancer detection in cirrhotic patients.

The company plans to utilize its January 2023 funding to enable the commercial development of HepatoPredict for the global market and the enhancement of other molecular tests.

## Funding rounds

- Series A, Jan 18, 2023 — BlueCrow Capital

## Investors

- BlueCrow Capital (https://capitalatlas.ai/funds/bluecrow-capital) — Series A